In addition, several clinical trials have produced evidence that PARP inhibitors have potent antitumor effects in BRCA-mutant PAAD (54), and these agents have been approved by the FDA for the treatment of metastatic PAAD in patients with BRCA mutations. This evidence concerns the gene PARP1 and pancreatic adenocarcinoma.